Legal & General Group’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Legal & General Group’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,961	Closed	-$14K	–	3723
2021 Q1	$14K	Sell	1,961 -95	-5%	-$782	﹤0.01%	3289
2020 Q4	$16K	Buy	2,056 +549	+36%	+$3.67K	﹤0.01%	3187
2020 Q3	$14K	Sell	1,507 -623	-29%	-$4.73K	﹤0.01%	3111
2020 Q2	$18K	Buy	2,130 +499	+31%	+$3.28K	﹤0.01%	3118
2020 Q1	$8K	Hold	1,631	–	–	﹤0.01%	3210
2019 Q4	$12K	Buy	1,631 +372	+30%	+$3.36K	﹤0.01%	3274
2019 Q3	$14K	Hold	1,259	–	–	﹤0.01%	3219
2019 Q2	$16K	Hold	1,259	–	–	﹤0.01%	3272
2019 Q1	$12K	Hold	1,259	–	–	﹤0.01%	3223
2018 Q4	$13K	Buy	+1,259	New	+$15.2K	﹤0.01%	3221

Other funds holding LOGC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Legal & General Group's LOGC Position: Q2 2021 in Review

Legal & General Group sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q2 2021, closing a stake of 1,961 shares — an estimated $14K sold.

Legal & General Group first reported a position in LOGC in Q4 2018 and held it in 10 quarters. The position peaked at $18K in Q2 2020. 63 funds tracked by Wall St. Rank hold LOGC as of Q2 2021.

Legal & General Group reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Legal & General Group sold 1,961 LogicBio Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $14K.
Legal & General Group first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 10 quarters.
Legal & General Group's LogicBio Therapeutics, Inc. Common Stock position peaked at $18K in Q2 2020.
63 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.